A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
about
Clinical outcomes in psoriatic arthritis: A systematic literature reviewSoluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placeboChange in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease statesChanges in FABP1 and gastrin receptor expression in the testes of rats that have undergone electrical injury.Synovial Tissue Response to Treatment with TNF Blockers in Peripheral SpondyloarthritisAlterations of Ca(v)1.2 and 5-hydroxytryptamine in rat hearts after positional asphyxia.Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.Steps in the management of psoriatic arthritis: a guide for clinicians.Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis.How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis.Biomarkers of cartilage and surrounding joint tissue.Biomarkers in psoriatic arthritis: recent progress.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Biomarkers in psoriatic arthritis: a systematic literature review.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.Synovial tissue hypoxia and inflammation in vivo.Synovial tissue response to treatment in psoriatic arthritis.Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint.Myeloid-related protein activity in rheumatoid arthritis.Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.Adalimumab for the treatment of psoriatic arthritis.A review on golimumab in the treatment of psoriatic arthritis.Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
P2860
Q26995307-5FEB0016-54F9-4F18-A181-ABCF8F8AAE76Q28475485-EBDCB0C7-A6DB-4624-A09D-B2230C51B6C9Q33390403-B9AAFB22-E5E0-409A-A9A2-8D7F1A5C0DC8Q33624763-BE6AA687-3959-4484-836C-2360D7127E5EQ34047769-BB50417E-F500-4DDE-91D3-1A5C936B85F0Q35681442-90460AB6-B53B-41D6-AB73-5D7B847A09D4Q35687019-ADB34BA9-E3EA-4345-B2AF-659A6373D6B5Q35809533-EE40BD35-66E7-4FFB-A72B-7158AA98217CQ36479450-C129E7AE-A49C-4014-8C73-10E9BA6B11A4Q36515480-55798F96-3315-4720-88F9-817068684250Q36970516-BB6F745B-5725-4DD2-9DC4-C481C056D912Q37520856-E7332710-1C48-4C79-BDDB-7446EF83F9F8Q37873493-A7A323E1-8FB3-412D-B3ED-DB162FBA942DQ38068590-AC138B31-103B-4FA2-928C-7AD5D85920ACQ38120525-CAFDBAAE-8212-44A7-94FF-10DC6DD34887Q38239828-E3D5BF95-9B0D-43B3-8A90-F5E269640FA0Q38248904-09ECF05F-DDDF-4117-B835-100D07E89159Q38630548-2D51C703-E193-4CAE-A2FF-143B3B0AFF84Q38715137-A0A6E0EE-25A2-4BF3-870C-AFF29E516A62Q38969036-2185A831-6467-497B-B54A-6A4B3EA882E7Q39708042-587636E4-9708-44BC-8552-F00AD59021F4Q40576433-551F62FE-9E44-4DC1-A09C-E5C586316033Q42420342-409FBB80-111F-45D2-A176-C0613F60CC63Q42870497-CAB597C0-A0EA-40AF-ABEA-065F889475B3Q48738063-7C45B928-BDA1-4DD6-B835-FA49DD31FA9DQ50960278-297DE01C-A778-409A-9DA5-0B627FB3AEFEQ51043569-BA999B5E-9DC5-43C0-8A9E-9E6D5BECB9CEQ52903765-54E72D2A-0D52-416D-8A52-9692897119C4Q53098976-4A49B8AC-D9EE-4125-85E5-036E5827B92AQ54978927-9A422CED-012F-4941-9667-F24CED80034E
P2860
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A prospective, randomised, pla ...... b treatment on synovial tissue
@en
A prospective, randomised, pla ...... treatment on synovial tissue.
@nl
type
label
A prospective, randomised, pla ...... b treatment on synovial tissue
@en
A prospective, randomised, pla ...... treatment on synovial tissue.
@nl
prefLabel
A prospective, randomised, pla ...... b treatment on synovial tissue
@en
A prospective, randomised, pla ...... treatment on synovial tissue.
@nl
P2093
P2860
P921
P356
P1476
A prospective, randomised, pla ...... b treatment on synovial tissue
@en
P2093
A H Zwinderman
A W R van Kuijk
B A C Dijkmans
D M Gerlag
M A de Rie
M de Groot
P2860
P304
P356
10.1136/ARD.2008.091389
P407
P577
2008-07-22T00:00:00Z